Targeting the gut-brain axis for therapeutic adherence in patients with inflammatory bowel disease: a review on the role of psychotherapy

References

• Zhang Y-Z, Li Y-Y. Inflammatory bowel disease: pathogenesis. WJG. 2014;20(1):91–99.
   PubMed Web of Science ®Google Scholar
• Garber A, Regueiro M. Extraintestinal manifestations of inflammatory bowel disease: epidemiology, etiopathogenesis, and management. Curr Gastroenterol Rep. 2019;21(7):31.
   PubMedGoogle Scholar
• Oligschlaeger Y, Yadati T, Houben T, et al. Inflammatory bowel disease: a stressed “gut/feeling. Cells. 2019;8(7):659.
   PubMed Web of Science ®Google Scholar
• Torres J, Ellul P, Langhorst J, et al. European crohn’s and colitis organisation topical review on complementary medicine and psychotherapy in inflammatory bowel disease. J Crohns Colitis. 2019;13(6):673–685e.
   PubMed Web of Science ®Google Scholar
• Knowles SR, Monshat K, Castle DJ. The efficacy and methodological challenges of psychotherapy for adults with inflammatory bowel disease: a review. Inflamm Bowel Dis. 2013;19(12):2704–2715.
   PubMed Web of Science ®Google Scholar
• McCombie AM, Mulder RT, Gearry RB. Psychotherapy for inflammatory bowel disease: a review and update. J Crohns Colitis. 2013;7(12):935–949.
   PubMed Web of Science ®Google Scholar
• Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720–727.
   PubMed Web of Science ®Google Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2020;14(1):4–22.
   PubMed Web of Science ®Google Scholar
• Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2–17.
   PubMedGoogle Scholar
• Lakatos PL. Prevalence, predictors, and clinical consequences of medical adherence in IBD: how to improve it? WJG. 2009;15(34):4234–4239.
   PubMed Web of Science ®Google Scholar
• Watanabe C, Nagahori M, Fujii T, et al. Non-adherence to medications in pregnant ulcerative colitis patients contributes to disease flares and adverse pregnancy outcomes. Dig Dis Sci. 2021;66(2):577–586.
   PubMed Web of Science ®Google Scholar
• Bager P, Julsgaard M, Vestergaard T, et al. Adherence and quality of care in IBD. Scand J Gastroenterol. 2016;51(11):1326–1331.
   PubMed Web of Science ®Google Scholar
• Colonnello V, Agostini A. Disease course, stress, attachment, and mentalization in patients with inflammatory bowel disease. Med Hypotheses. 2020;140:109665.
   PubMed Web of Science ®Google Scholar
• Neuendorf R, Harding A, Stello N, et al. Depression and anxiety in patients with inflammatory bowel disease: a systematic review. J Psychosom Res. 2016;87:70–80.
   PubMed Web of Science ®Google Scholar
• Barberio B, Zamani M, Black CJ, et al. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(5):359–370.
   PubMed Web of Science ®Google Scholar
• Sontakke S, Budania R, Bajait C, et al. Evaluation of adherence to therapy in patients of chronic kidney disease. Indian J Pharmacol. 2015;47(6):668–671.
   PubMed Web of Science ®Google Scholar
• Copeland LA, Zeber JE, Salloum IM, et al. Treatment adherence and illness insight in veterans with bipolar disorder. J Nerv Ment Dis. 2008;196(1):16–21.
   PubMed Web of Science ®Google Scholar
• Tong P, Bu P, Yang Y, et al. Group cognitive behavioural therapy can reduce stigma and improve treatment compliance in major depressive disorder patients. Early Interv Psychiatry. 2020;14(2):172–178.
   PubMed Web of Science ®Google Scholar
• Gracie DJ, Hamlin PJ, Ford AC. The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment. Lancet Gastroenterol Hepatol. 2019;4(8):632–642.
   PubMed Web of Science ®Google Scholar
• Günther C, Rothhammer V, Karow M, et al. The gut-brain axis in inflammatory bowel disease-current and future perspectives. IJMS. 2021;22(16):8870.
   Google Scholar
• Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660–1666.
   PubMed Web of Science ®Google Scholar
• Gracie DJ, Williams CJM, Sood R, et al. Poor correlation between clinical disease activity and mucosal inflammation, and the role of psychological comorbidity, in inflammatory bowel disease. Am J Gastroenterol. 2016;111(4):541–551.
   PubMed Web of Science ®Google Scholar
• Targownik LE, Sexton KA, Bernstein MT, et al. The relationship among perceived stress, symptoms, and inflammation in persons with inflammatory bowel disease. Am. J Gastroenterol. 2015;110(7):1001–1012. quiz 1013.
   Web of Science ®Google Scholar
• Fond G, Loundou A, Hamdani N, et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2014;264(8):651–660.
   PubMed Web of Science ®Google Scholar
• Mayer EA, Labus J, Aziz Q, et al. Role of brain imaging in disorders of brain-gut interaction: a rome working team report. Gut. 2019;68(9):1701–1715.
   PubMed Web of Science ®Google Scholar
• Lee I-S, Wang H, Chae Y, et al. Functional neuroimaging studies in functional dyspepsia patients: a systematic review. Neurogastroenterol. Motil. 2016;28(6):793–805.
   PubMed Web of Science ®Google Scholar
• Jones MP, Tack J, Van Oudenhove L, et al. Mood and anxiety disorders precede development of functional gastrointestinal disorders in patients but not in the population. Clin Gastroenterol Hepatol. 2017;15(7):1014–1020.e4.
   PubMed Web of Science ®Google Scholar
• Banerjee R, Pal P, Adigopula B, et al. Impact of demographic, clinical and psychosocial variables on drug adherence and outcomes in indian patients with inflammatory bowel disease: cost is not the only factor. J Clin Gastroenterol. 2021;55(10):e92–e99.
   PubMed Web of Science ®Google Scholar
• Nahon S, Lahmek P, Durance C, et al. Risk factors of anxiety and depression in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2086–2091.
   PubMed Web of Science ®Google Scholar
• Selinger CP, Robinson A, Leong RW. Clinical impact and drivers of non-adherence to maintenance medication for inflammatory bowel disease. Expert Opin Drug Saf. 2011;10(6):863–870.
   PubMed Web of Science ®Google Scholar
• Cushman GK, Shih S, Stolz MG, et al. Stressful life events, depression, and the moderating role of psychophysiological reactivity in patients with pediatric inflammatory bowel disease. J Psychosom Res. 2021;141:110323.
   PubMed Web of Science ®Google Scholar
• López-Sanromán A, Bermejo F. Review article: how to control and improve adherence to therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24(s3):45–49.
   PubMedGoogle Scholar
• Dolovich C, Bernstein CN, Singh H, et al. Anxiety and depression leads to anti-tumor necrosis factor discontinuation in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2021;19(6):1200–1208.e1.
   PubMed Web of Science ®Google Scholar
• Araki M, Shinzaki S, Yamada T, et al. Psychologic stress and disease activity in patients with inflammatory bowel disease: a multicenter cross-sectional study. PLOS One. 2020;15(5):e0233365.
   PubMed Web of Science ®Google Scholar
• Shaw L, Ehrlich A. Relaxation training as a treatment for chronic pain caused by ulcerative colitis. Pain. 1987;29(3):287–293.
   PubMed Web of Science ®Google Scholar
• García-Vega E, Fernandez-Rodriguez C. A stress management programme for Crohn’s disease. Behav Res Ther. 2004;42(4):367–383.
   PubMed Web of Science ®Google Scholar
• Vogelaar L, Van’t Spijker A, Vogelaar T, et al. Solution focused therapy: a promising new tool in the management of fatigue in Crohn’s disease patients psychological interventions for the management of fatigue in Crohn’s disease. J Crohns Colitis. 2011;5(6):585–591.
   PubMed Web of Science ®Google Scholar
• Keefer L, Kiebles JL, Kwiatek MA, et al. The potential role of a self-management intervention for ulcerative colitis: a brief report from the ulcerative colitis hypnotherapy trial. Biol Res Nurs. 2012;14(1):71–77.
   PubMed Web of Science ®Google Scholar
• Grootenhuis MA, Maurice-Stam H, Derkx BH, et al. Evaluation of a psychoeducational intervention for adolescents with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2009;21:340–345.
   PubMed Web of Science ®Google Scholar
• Timmer A, Preiss JC, Motschall E, et al. Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database Syst Rev. 2011;(2):CD006913. doi: 10.1002/14651858.CD006913.pub2. PMID: 21328288
   Google Scholar
• Oliveira S, Zaltman C, Elia C, et al. Quality-of-life measurement in patients with inflammatory bowel disease receiving social support. Inflamm Bowel Dis. 2007;13:470–474.
   PubMed Web of Science ®Google Scholar
• Smith GD, Watson R, Roger D, et al. Impact of a nurse-led counselling service on quality of life in patients with inflammatory bowel disease. J Adv Nurs. 2002;38(2):152–160.
   PubMed Web of Science ®Google Scholar
• Langhorst J, Mueller T, Luedtke R, et al. Effects of a comprehensive lifestyle modification program on quality-of-life in patients with ulcerative colitis: a twelve-month follow-up. Scand J Gastroenterol. 2007;42(6):734–745.
   PubMed Web of Science ®Google Scholar
• van den Brink G, Stapersma L, Bom AS, et al. Effect of cognitive behavioral therapy on clinical disease course in adolescents and young adults with inflammatory bowel disease and subclinical anxiety and/or depression: results of a randomized trial. Inflamm Bowel Dis. 2019;25(12):1945–1956.
   PubMed Web of Science ®Google Scholar
• Ewais T, Begun J, Kenny M, et al. Mindfulness based cognitive therapy for youth with inflammatory bowel disease and depression - Findings from a pilot randomised controlled trial. J Psychosom Res. 2021;149:110594.
   PubMed Web of Science ®Google Scholar
• Norton C, Czuber-Dochan W, Artom M, et al. Systematic review: interventions for abdominal pain management in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46(2):115–125.
   PubMed Web of Science ®Google Scholar
• Farrell D, Artom M, Czuber-Dochan W, et al. Interventions for fatigue in inflammatory bowel disease. Cochrane Database Syst Rev. 2020;4:CD012005.
   PubMed Web of Science ®Google Scholar
• Stapersma L, van den Brink G, van der Ende J, et al. Psychological outcomes of a cognitive behavioral therapy for youth with inflammatory bowel disease: results of the HAPPY-IBD randomized controlled trial at 6- and 12-month follow-up. J Clin Psychol Med Settings. 2020;27(3):490–506.
   PubMed Web of Science ®Google Scholar
• Chen J, Chen X, Sun Y, et al. The physiological and psychological effects of cognitive behavior therapy on patients with inflammatory bowel disease before COVID-19: a systematic review. BMC Gastroenterol. 2021;21(1):469.
   PubMed Web of Science ®Google Scholar
• Jantschek G, Zeitz M, Pritsch M, et al. Effect of psychotherapy on the course of Crohn’s disease. Results of the german prospective multicenter psychotherapy treatment study on Crohn’s disease. German study group on psychosocial intervention in Crohn’s disease. Scand J Gastroenterol. 1998;33:1289–1296.
   PubMed Web of Science ®Google Scholar
• Deter H-C, Keller W, von Wietersheim J, et al. Psychological treatment may reduce the need for healthcare in patients with Crohn’s disease. Inflamm Bowel Dis. 2007;13:745–752.
   PubMed Web of Science ®Google Scholar
• Hommel KA, Herzer M, Ingerski LM, et al. Individually tailored treatment of medication nonadherence. J Pediatr Gastroenterol Nutr. 2011;53(4):435–439.
   PubMed Web of Science ®Google Scholar
• Wenzel A. Basic strategies of cognitive behavioral therapy. Psychiatr Clin North Am. 2017;40(4):597–609.
   PubMed Web of Science ®Google Scholar
• Oar EL, Johnco C, Ollendick TH. Cognitive behavioral therapy for anxiety and depression in children and adolescents. Psychiatr Clin North Am. 2017;40(4):661–674.
   PubMed Web of Science ®Google Scholar
• Kaczkurkin AN, Foa EB. Cognitive-behavioral therapy for anxiety disorders: an update on the empirical evidence. Dialogues Clin Neurosci. 2015;17(3):337–346.
   PubMed Web of Science ®Google Scholar
• Hommel KA, Hente EA, Odell S, et al. Evaluation of a group-based behavioral intervention to promote adherence in adolescents with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2012;24:64–69.
   PubMed Web of Science ®Google Scholar
• Keefer L, Doerfler B, Artz C. Optimizing management of Crohn’s disease within a project management framework: results of a pilot study. Inflamm Bowel Dis. 2012;18:254–260.
   PubMed Web of Science ®Google Scholar
• Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74.
   PubMed Web of Science ®Google Scholar
• Hommel KA, Hente E, Herzer M, et al. Telehealth behavioral treatment for medication nonadherence: a pilot and feasibility study. Eur J Gastroenterol Hepatol. 2013;25(4):469–473.
   PubMed Web of Science ®Google Scholar
• Antal-Uram D, Harsányi L, Perczel-Forintos D. [Low-intensity, evidence-based cognitive-behavioural therapy of a patient with Crohn’s disease]. Orv Hetil. 2018;159(9):363–369.
   PubMed Web of Science ®Google Scholar
• Ewais T, Begun J, Kenny M, et al. Protocol for a pilot randomised controlled trial of mindfulness-based cognitive therapy in youth with inflammatory bowel disease and depression. BMJ Open. 2019;9(4):e025568.
   PubMedGoogle Scholar
• Abbott RA, Whear R, Rodgers LR, et al. Effectiveness of mindfulness-based stress reduction and mindfulness based cognitive therapy in vascular disease: a systematic review and meta-analysis of randomised controlled trials. J Psychosom Res. 2014;76(5):341–351.
   PubMed Web of Science ®Google Scholar
• Luders E, Clark K, Narr KL, et al. Enhanced brain connectivity in long-term meditation practitioners. Neuroimage. 2011;57(4):1308–1316.
   PubMed Web of Science ®Google Scholar
• Keefer L, Taft TH, Kiebles JL, et al. Gut-directed hypnotherapy significantly augments clinical remission in quiescent ulcerative colitis. Aliment Pharmacol Ther. 2013;38(7):761–771.
   PubMed Web of Science ®Google Scholar
• Peters SL, Yao CK, Philpott H, et al. Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2016;44(5):447–459.
   PubMed Web of Science ®Google Scholar
• Peters SL, Muir JG, Gibson PR. Review article: gut-directed hypnotherapy in the management of irritable bowel syndrome and inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41(11):1104–1115.
   PubMed Web of Science ®Google Scholar
• Calvert EL, Houghton LA, Cooper P, et al. Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology. 2002;123(6):1778–1785.
   PubMed Web of Science ®Google Scholar
• Sharma RL. Functional dyspepsia: at least recommend hypnotherapy. BMJ. 2008;337:a1972.
   PubMedGoogle Scholar
• Chiarioni G, Vantini I, De Iorio F, et al. Prokinetic effect of gut-oriented hypnosis on gastric emptying. Aliment Pharmacol Ther. 2006;23(8):1241–1249.
   PubMed Web of Science ®Google Scholar
• Hypnotherapy for duodenal ulcer. Lancet. 1988. 2:159–160.
   Google Scholar
• Dorfman L, Nassar R, Binjamin Ohana D, et al. Pediatric inflammatory bowel disease and the effect of COVID-19 pandemic on treatment adherence and patients’ behavior. Pediatr Res. 2021;90(3):637–641.
   PubMed Web of Science ®Google Scholar
• Gomollón F. Treatment adherence is always worse than we think: an unresolved problem in inflammatory bowel disease. Gastroenterol Hepatol. 2016;39(Suppl 1):14–19.
   PubMedGoogle Scholar
• Salehi C, Mansfield KJ, Lee T. Predictors of receptivity to psychotherapy in inflammatory bowel disease. J Gastroenterol Hepatol. 2016. 31:145.
   Google Scholar
• D'Incà R, Bertomoro P, Mazzocco K, et al. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2008;27(2):166–172.
   PubMed Web of Science ®Google Scholar
• Magalhães J, Dias de Castro F, Boal Carvalho P, et al. Treatment of inflammatory bowel disease: is your patient at risk of non-adherence? Acta Med Port. 2014;27(5):576–580.
   PubMed Web of Science ®Google Scholar
• van der Have M, Oldenburg B, Kaptein AA, et al. Non-adherence to anti-TNF therapy is associated with illness perceptions and clinical outcomes in outpatients with inflammatory bowel disease: results from a prospective multicentre study. J Crohns Colitis. 2016;10(5):549–555.
   PubMed Web of Science ®Google Scholar
• Horne R, Parham R, Driscoll R, et al. Patients’ attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:837–844.
   PubMed Web of Science ®Google Scholar
• Lopez A, Billioud V, Peyrin-Biroulet C, et al. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis. 2013;19(7):1528–1533.
   PubMed Web of Science ®Google Scholar
• Wentworth BJ, Buerlein RCD, Tuskey AG, et al. Nonadherence to biologic therapies in inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(9):2053–2061.
   PubMed Web of Science ®Google Scholar
• Devlen J, Beusterien K, Yen L, et al. Barriers to mesalamine adherence in patients with inflammatory bowel disease: a qualitative analysis. J Manag Care Spec Pharm. 2014;20(3):309–314.
   PubMed Web of Science ®Google Scholar
• Greenley RN, Karazsia B, Schurman JV, et al. Trajectories of oral medication adherence in youth with inflammatory bowel disease. Health Psychol. 2015;34(5):514–521.
   PubMed Web of Science ®Google Scholar
• Herman ML, Kane SV. Treatment nonadherence in inflammatory bowel disease: identification, scope, and management strategies. Inflamm Bowel Dis. 2015;21(12):2979–2984.
   PubMed Web of Science ®Google Scholar
• Gray WN, Denson LA, Baldassano RN, et al. Treatment adherence in adolescents with inflammatory bowel disease: the collective impact of barriers to adherence and anxiety/depressive symptoms. J Pediatr Psychol. 2012;37(3):282–291.
   PubMed Web of Science ®Google Scholar
• Vangeli E, Bakhshi S, Baker A, et al. A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther. 2015;32(11):983–1028.
   PubMed Web of Science ®Google Scholar
• Knowles SR, Alex G. Medication adherence across the life span in inflammatory bowel disease: implications and recommendations for nurses and other health providers. Gastroenterol Nurs. 2020;43(1):76–88.
   PubMed Web of Science ®Google Scholar
• Bhatt J, Patil S, Joshi A, et al. Self-reported treatment adherence in inflammatory bowel disease in indian patients. Indian J Gastroenterol. 2009;28(4):143–146.
   PubMedGoogle Scholar
• Calvo-Arbeloa M, Insausti-Serrano AM, Arrondo-Velasco A, et al. Adherence to treatment with adalimumab, golimumab and ustekinumab in patients with inflammatory bowel disease. Farm Hosp. 2020;44:62–67.
   PubMed Web of Science ®Google Scholar
• Nguyen GC, LaVeist TA, Harris ML, et al. Patient trust-in-physician and race are predictors of adherence to medical management in inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1233–1239.
   PubMed Web of Science ®Google Scholar
• Nahon S, Lahmek P, Saas C, et al. Socioeconomic and psychological factors associated with nonadherence to treatment in inflammatory bowel disease patients: results of the ISSEO survey. Inflamm Bowel Dis. 2011;17(6):1270–1276.
   PubMed Web of Science ®Google Scholar
• Kim MC, Jung YS, Song YS, et al. Factors associated with anxiety and depression in korean patients with inactive inflammatory bowel disease. Gut Liver. 2016;10(3):399–405.
   PubMed Web of Science ®Google Scholar
• Greuter T, Manser C, Pittet V, , et al. Gender differences in inflammatory bowel disease. Digestion. 2020;101 Suppl 1(Suppl 1):98–104.
   PubMed Web of Science ®Google Scholar
• Andrade LD, Oliveira FA, Mariano VD, et al. Adherence to medical treatment in inflammatory bowel disease patients from a referral center in Bahia-Brazil. Biomed Res Int. 2020;2020:5269493. 2020:
   PubMed Web of Science ®Google Scholar
• Ribaldone DG, Vernero M, Astegiano M, et al. How ameliorate the adherence in patients with inflammatory bowel disease? Scand J Gastroenterol. 2018;53(8):938–939.
   PubMed Web of Science ®Google Scholar
• Tahri N. [Treatment adherence and chronic inflammatory bowel diseases]. Presse Med. 2007;36(9 Pt 2):1236–1243.
   PubMed Web of Science ®Google Scholar
• Jackson CA, Clatworthy J, Robinson A, et al. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2010;105(3):525–539.
   PubMed Web of Science ®Google Scholar
• Robinson A. Review article: improving adherence to medication in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27 Suppl 1:9–14.
   PubMed Web of Science ®Google Scholar
• Lai C, Sceats LA, Qiu W, et al. Patient decision-making in severe inflammatory bowel disease: the need for improved communication of treatment options and preferences. Colorectal Dis. 2019;21(12):1406–1414.
   PubMed Web of Science ®Google Scholar